Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
Suven Life Sciences will be presenting several data presentation from their portfolio of investigational neuroscience new chemical entities (NCEs) at SFN from 13th to 16th of November at Washington, DC, US. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30,000 Neuro scientists from all over the world covering all the major Pharma, biotech and research institutes will be participating.
Suven’s nine data presentation covers the early stage compounds from Histamine 3receptor antagonist, Nicotinic acetylcholine alpha- beta-2 receptor agonist and antagonist, Serotonin 5-HT4 receptor against in addition to 5HT6 antagonists to treat unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer’s, Schizophrenia, ADHD; Depression and Mood disorders and Neuropathic pain.
These data presentation highlights company’s continued commitment to exploring new treatment options addressing unmet medical need through novel mechanism and targets and address a market size of more than $30 billon.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1687.55 |
Dr. Reddys Lab | 1109.15 |
Cipla | 1463.15 |
Lupin | 1969.05 |
Zydus Lifesciences | 868.25 |
View more.. |